Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Iloprost for COVID-19 Respiratory Failure
NCT04445246Phase 2Completed
- Sponsor
- Hamad Medical Corporation
- Start
- May 2020
- Primary completion
- May 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of iloprost in coronavirus disease 2019 (COVID-19), hypoxemic respiratory failure, sponsored by Hamad Medical Corporation. Started May 2020; status: completed.
02
Drugs
iloprost
03
Conditions
coronavirus disease 2019 (COVID-19)hypoxemic respiratory failure
Beyond the preview
Go deeper on NCT04445246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04445246.